Eirion Therapeutics Hair Growth ET-02 ET-03
After a slow and disappointing winter season in 2024, we start the year with some positive news in the androgenic alopecia space. Eirion Therapeutics, a clinical-stage biopharmaceutical company with oral and topical androgenic alopecia treatments in the pipeline, has announced results from their 4-week androgenic alopecia trial of topical ET-02. What Is ET-02? We don’t…
Read More
There is more news in the androgenic alopecia space, as Eirion Therapeutics begins a Phase 1 trial for ET-02, a topical treatment. What is ET-02? According to Eirion Therapeutics, ET-02 works by targeting hair follicle stem cells that have become defective or inactive in individuals suffering from androgenic alopecia, enabling hair follicles to resume normal…
Read More
Today, we begin a series of articles on new companies entering the hair growth industry. One of these companies, Eirion Therapeutics, has treatments for androgenic alopecia as well as hair graying in their pipeline. Topadur Pharma M119 Based in Switzerland, Topadur Pharma is a clinical stage pharmaceutical company with a focus on the cGMP (cyclic…
Read More